Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 January 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Changing burden of Hepatitis C virus infection in the United States

The latest issue of the Annals of Internal Medicine makes predictions on the changing burden of Hepatitis C virus infection.

News image

fiogf49gjkf04

Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease.

Dr Chhatwal and colleagues from Texas, USA predicted the effect of new therapies and screening on chronic HCV infection and associated disease outcomes.

The research team evaluated existing and anticipated therapies and screening for HCV infection in the United States.

The team assessed the total HCV-infected population in the United States.

Outcomes included the number of cases of chronic HCV infection and outcomes of advanced-stage HCV infection.
Chronic HCV cases decreased from 3.2 million in 2001 to 2.3 million in 2013
Annals of Internal Medicine

The number of cases of chronic HCV infection decreased from 3.2 million in 2001 to 2.3 million in 2013.

The researchers report that 1-time birth-cohort screening beginning in 2013 is expected to identify 487,000 cases of HCV infection in the next 10 years.

In contrast, 1-time universal screening could identify 933,700 cases.

With the availability of highly effective therapies, HCV infection could become a rare disease in the next 22 years.

The team found that recently approved therapies for HCV infection and 1-time birth-cohort screening could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular carcinoma, 126,500 liver-related deaths, and 9900 liver transplantations by 2050.

Increasing the treatment capacity would further reduce the burden of HCV disease.

Dr Chhatwal's team concludes, "New therapies for HCV infection and widespread implementation of screening and treatment will play an important role in reducing the burden of HCV disease."

"More aggressive screening recommendations are needed to identify a large pool of infected patients."

Ann Intern Med 2014; 161(3): 170-180
06 August 2014

Go to top of page Email this page Email this page to a colleague

 19 January 2017 
Infliximab treatment algorithm in IBD
 19 January 2017 
Radiation exposure in IBD and IBS 
 19 January 2017 
Prediction of chronic liver disease mortality
 18 January 2017 
Measure of GERD
 18 January 2017 
Helicobacter pylori eradication and insulin resistance
 18 January 2017 
Hormone levels and NAFLD severity
 17 January 2017 
Pediatric-onset Crohn's disease
 17 January 2017 
Biologic drugs and extraintestinal manifestations in IBD
 17 January 2017 
Colorectal cancer prevention among Medicare beneficiaries
 16 January 2017 
HCV eradication in cirrhosis
 16 January 2017 
Thyroid and primary biliary cholangitis
 16 January 2017 
Sarcopenia and severe liver fibrosis
 13 January 2017 
Early monocytopenia in paracetamol-induced liver failure
 13 January 2017 
Anti-TNF discontinuation in patients with IBD
 13 January 2017 
Isolated colonic Crohn's disease
 12 January 2017 
Providing relief for chronic constipation
 12 January 2017 
Internet-delivered therapy for adolescents with IBS
 12 January 2017 
NAFLD and coronary artery calcium score
 11 January 2017 
Fatigue in IBD
 11 January 2017 
Pancreatic cancer risk with asthma and nasal allergies
 11 January 2017 
PPIs and bone strength and structure
 10 January 2017 
Colorectal cancer risk in serrated polyposis syndrome
 10 January 2017 
Evaluation of abnormal liver chemistries
 10 January 2017 
Pelvic physiotherapy in functional constipation
 09 January 2017 
Intestinal microbiota and IBS
 09 January 2017 
Helicobacter and Campylobacter in IBD
 09 January 2017 
Diagnosis of microscopic colitis
 06 January 2017 
Recommendations on colorectal cancer screening 
 06 January 2017 
Colorectal cancer susceptibility gene variants
 06 January 2017 
Thiopurine-induced hepatotoxicity in IBD
 05 January 2017 
Histological index for ulcerative colitis
 05 January 2017 
Crohn's disease after total colectomy with permanent ileostomy
 05 January 2017 
Celiac disease screening in IBS
 04 January 2017 
Serrated colorectal polyps risk factors
 04 January 2017 
Score to predict eosinophilic esophagitis
 04 January 2017 
Platelet transfusion for gastrointestinal bleeding
 03 January 2017 
Pelvic physiotherapy for functional constipation in children
 03 January 2017 
Tumor necrosis factor antagonists in IBD
 03 January 2017 
Mesenchymal stromal cell therapy for IBD
 22 December 2016 
Happy holidays!
 21 December 2016 
Pharmacotherapy for NAFLD
 21 December 2016 
Predicting disease activity in eosinophilic esophagitis
 21 December 2016 
Breath Testing for Barrett’s esophagus
 20 December 2016 
H. pylori on the ethnic distribution of Barrett's metaplasia
 20 December 2016 
Prognostic biomarker in colorectal cancer
 20 December 2016 
Online health information for colorectal cancer screening
 19 December 2016 
Risk of tuberculosis in IBD
 19 December 2016 
Risk of complications of percutaneous liver biopsy
 19 December 2016 
Hospital research and colorectal cancer survival
 16 December 2016 
Mortality rates for major causes of death
 16 December 2016 
Non-invasive genomic biomarkers for colorectal cancer
 16 December 2016 
Predicting organ failure in acute pancreatitis
 15 December 2016 
Adjuvant chemotherapy use varies for advance colon cancer
 15 December 2016 
Histological index for ulcerative colitis
 15 December 2016 
Readmission after acute upper GI bleed
 14 December 2016 
Fecal microbiota transfer
 14 December 2016 
Colorectal cancer screening in primary care
 14 December 2016 
Management of H. pylori infection
 13 December 2016 
Caffeine and hepatitis C virus infection
 13 December 2016 
Clinical relapse among patients with ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us